Skip to Main Content

Paper Details

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Clin Cancer Res
38
2018
/, ANBL0032, Dinutuximab, GM-CSF, HLA-Bw4, HLA-C1, IL2, KIR, KIR-, KIR-Ligand Genotypes, KIR-ligand, KIR-ligands, KIR3DL1, Killer immunoglobulin-like receptors, NK cells, Neuroblastoma, Patients, cancer, chimeric anti-GD2 monoclonal antibody, dinutuximab, isotretinoin, natural, natural killer (NK) cells, neuroblastoma, patients
Author NameAffiliation
Eneida A MendoncaUniversity of Wisconsin
Eneida A MendoncaUniversity of Wisconsin
Susan L CohnUniversity of Chicago
Michael D HogartyChildren's Hospital of Philadelphia and University of Pennsylvania School of Medicine
John M MarisChildren's Hospital of Philadelphia and University of Pennsylvania School of Medicine
John M MarisChildren's Hospital of Philadelphia and University of Pennsylvania School of Medicine
  • 1 - 6

Datasets

Release 1.2